Abstract
Introduction: hansen’s disease, also known as leprosy, is an infection caused by Mycobacterium leprae. Leprosy reactions may occur before, during, or after the completion of multidrug therapy and result from changes in the immune balance between the host and M. leprae. These reactions are acute inflammatory episodes that primarily affect the skin and nerves and are the leading cause of morbidity and neurological disability in leprosy. Identifying the demographic and clinical profile for leprosy reactions is essential for early detection and timely management to prevent complications that may lead to long-term disability. Understanding the sociodemographic and clinical profiles of affected patients can help guide effective strategies for improving patient care and health service delivery. Methods: a descriptive cross-sectional study was conducted to assess the relationship between characteristics and the occurrence of leprosy reactions among leprosy patients seen and treated at a public tertiary hospital in Pasig, Philippines, from 2018 to 2022. Secondary data were collected from medical records and hospital documents. Results: a total of 40 patients with leprosy were included. Most were male, resided outside the National Capital Region, and were in the 20-39 age group. Clinically, the majority were classified as lepromatous leprosy and fell under the multibacillary treatment regimen, with no extensions in treatment duration. Type I reactions were more common than type II reactions and occurred predominantly during multidrug therapy. Most patients experiencing leprosy reactions were started on prednisone 40 mg daily. The average bacteriological index showed significant improvement from pre- to post-treatment. The most frequently reported signs and symptoms included erythema and tenderness of existing lesions for type I reactions, and painful, tender nodules for type II reactions. Age, sex, leprosy spectrum, and treatment duration showed no statistically significant associations with leprosy reactions (p > 0.05). Conclusion: this study found no statistically significant associations between the sociodemographic characteristics (age and sex) and clinical characteristics (leprosy spectrum, treatment regimen classification, and treatment compliance) and the type of leprosy reaction among leprosy patients treated at a public tertiary hospital from 2018 to 2022.
References
1. Centers for Disease Control and Prevention. Leprosy (Hansen’s Disease). USA: CDC; 2023. [cited 2024 Aug. 15]. Available from: https://www.cdc.gov/leprosy/index.html#:~:text=Hansen’s%20disease.
2. World Health Organization. Leprosy. WHO; 2023. [cited 2024 Aug. 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/leprosy.
3. Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al. (Eds.). Fitzpatrick’s Dermatology. 9e. New York: McGraw-Hill; 2019.
4. Scollard DM, Martelli CM, Stefani MM, Maroja M de F, Villahermosa L, Pardillo F, et al. Risk factors for leprosy reactions in three endemic countries. Am J Trop Med Hyg. 2015 Jan;92(1):108-14. doi: https://doi.org/10.4269/ajtmh.13-0221.
5. Ghafoor R, Anwar MI, Zia M. Lepra reactions in new leprosy cases at diagnosis: A study of 50 Pakistani patients. J Pak Med Assoc. 2021 Mar;71(3):838-842. doi: https://doi.org/10.47391/JPMA.878.
6. Paula HL, Souza CDF, Silva SR, Martins-Filho PRS, Barreto JG, Gurgel RQ, et al. Risk factors for physical disability in patients with leprosy: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(10):1120-8. doi: https://doi.org/10.1001/jamadermatol.2019.1768.
7. Kahawita IP, Walker SL, Lockwood DN. Leprosy type 1 reactions and erythema nodosum leprosum. An Bras Dermatol. 2008;83(1):75-82.
8. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006 Apr;19(2):338-81. doi: https://doi.org/10.1128/CMR.19.2.338-381.2006.
9. Putri AI, de Sabbata K, Agusni RI, Alinda MD, Darlong J, de Barros B, et al. Understanding leprosy reactions and the impact on the lives of people affected: an exploration in two leprosy endemic countries. PLoS Negl Trop Dis. 2022;16(6):e0010476. doi: https://doi.org/10.1371/journal.pntd.0010476.
10. Ramadhona A, Supriyanto S, Martini S. Prevention effort of leprosy reactions based on risk factor analysis at Sumberglagah Leprosy Hospital, Mojokerto. KnE Life Sciences. 2018;4(9):161-71. doi: https://doi.org/10.18502/kls.v4i9.3568.
11. Richardus JH, Habbema JD. The impact of leprosy control on the transmission of M. leprae: is elimination being attained? Lepr Rev. 2007 Dec;78(4):330-7. doi: https://doi.org/10.47276/lr.78.4.330.
12. Yotsu RR, Miyamoto Y, Mori S, Ato M, Sugawara-Mikami M, Yamaguchi S, et al. Hansen’s disease (leprosy) in Japan, 1947-2020: an epidemiologic study during the declining phase to elimination. Int J Infect Dis. 2022 Dec;125:265-74. doi: https://doi.org/10.1016/j.ijid.2022.10.027.
13. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859-922. doi: https://doi.org/10.1016/S0140-6736(18)32335-3.
14. World Health Organization. Leprosy (Hansen’s disease) [Internet].2023. [cited 2024 Aug. 15]. Available from: https://www.who.int/data/gho/data/themes/topics/leprosy-hansens-disease.
15. Kumar A, Girdhar A, Chakma JK. Incidence of leprosy in Firozabad district (Uttar Pradesh). Indian J Dermatol Venereol Leprol. 2018 Jul-Aug;84(4):403-7. doi: https://doi.org/10.4103/ijdvl.IJDVL_908_15.
16. Antunes DE, Araújo S, Ferreira GP, Cunha AC, Costa AV, Gonçalves MA, et al. Identification of clinical, epidemiological, and laboratory risk factors for leprosy reactions during and after multidrug therapy. Mem Inst Oswaldo Cruz. 2013 Nov;108(7):901-8. doi: https://doi.org/10.1590/0074-0276130222.
17. Hungria EM, Oliveira RM, Penna GO, Aderaldo LC, de Pontes MA, Cruz R, et al. Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil. Infect Dis Poverty. 2016;5(1):110. doi: http://doi. org/10.1186/s40249-016-0203-0.
18. Rosdiana B, Astari L, Astindari A, Prakoeswa CRS, Zulkarnain I, Damayanti D, et al. Risk factors of type 1 leprosy reaction in leprosy patients attending leprosy division of dermatology and venereology outpatient clinic of Dr. Soetomo General Hospital in 2017-2019: a retrospective study. Open Access Maced J Med Sci. 2021 Oct.15;9(B):1359-63. doi: https://doi.org/10.3889/oamjms.2021.7201.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Issa Janine Acanto, Abelaine Tablizo